Chicago, November 17, 2025 — Leads & Copy — Galderma presented new data from its Injectable Aesthetics portfolio and pipeline at the American Society for Dermatologic Surgery (ASDS) 2025 Annual Meeting, held November 13-16 in Chicago.
Six poster presentations highlighted the latest data on Restylane, Sculptra, and Relfydess, while onsite educational events through the Galderma Aesthetic Injector Network (GAIN) showcased Galderma’s commitment to advancing aesthetic medicine through science-backed solutions. The findings reinforce Galderma’s leadership in delivering meaningful outcomes and addressing unmet patient needs through clinical evidence and practitioner education.
Galderma’s portfolio delivers high patient satisfaction and responds to emerging aesthetic needs. Pivotal new data from Galderma’s Restylane portfolio reinforced its versatility in delivering natural-looking, personalized aesthetic outcomes. In the first of three pivotal studies, treatment with Restylane Lyft improved the chin profile in patients with mild-to-moderate chin retrusion.
Both investigators and patients reported high satisfaction (≥89%), with 84% and 70% of patients showing visible aesthetic improvements at Months 3 and 12, respectively. From Months 3 to 12, most patients treated with Restylane were satisfied with the overall appearance of their lower face (≥78%), the natural look of their chin projection (≥86%), and the sculpted, well-defined appearance of their jawline (≥81%).
Restylane Lyft with Lidocaine was recently approved by the U.S. Food and Drug Administration for augmentation of the chin region to improve the chin profile in patients over 21 with mild-to-moderate chin retrusion. Restylane Lyft is also approved to treat the midface, facial folds and wrinkles (such as nasolabial folds) and back of hands.
Nine-month results from a phase IV study presented at ASDS 2025 demonstrate that treatment with Sculptra in a regimen with Restylane Lyft or Restylane Contour effectively improved facial wrinkles, loss of firmness, and contour deficiencies in patients experiencing facial volume loss following medication-driven weight loss. Sculptra’s regenerative properties supported collagen and elastin production, delivering lasting improvements in skin radiance, while Restylane Lyft enhanced skin hydration. Patients reported high satisfaction with results as early as Week 4 that was maintained through to Month 9, and treatments were well tolerated, with no treatment-related adverse events reported.
To further explore this emerging patient profile, Galderma hosted an expert-led lunch and learn session titled, “Meeting the Emerging Facial Aesthetic Needs of the GLP-1 Weight-Loss Patient featuring Live Injections of Sculptra and Restylane,” featuring aesthetics experts Dr. Steve Dayan, Dr. Carolyn Jacob, and Emily Ann Scalise.
Results from two additional pivotal studies of Restylane showed consistently high response rates, sustained aesthetic improvements, and strong satisfaction levels among both patients and investigators when addressing temple hollowing and wrinkles in the décolletage. Restylane Skinboosters significantly improved wrinkles and skin hydration in the décolletage area for patients with moderate-to-severe wrinkles. High response rates were observed at Week 12 (74%) and sustained through Weeks 24 and 32. Both patients and investigators consistently reported high aesthetic improvement rates (≥82%) from Week 12 to 32. Additionally, skin hydration improved at Week 12, with patients expressing high satisfaction with skin texture (≥76%), smoothness (≥74%), and wrinkle appearance (≥83%).
In patients with moderate-to-severe temple hollowing, Restylane Contour effectively improved temple volume, demonstrating consistently high response rates at Month 3 (91%), Month 12 (92%) and Month 18 (86%). Aesthetic improvements were long-lasting through to Month 18. From Month 3 to 18, patients reported high satisfaction with the appearance of their temples (≥84%), and with how natural their temples looked (≥85%) and felt (≥85%). Across all studies, safety outcomes were consistent with Restylane’s three-decade safety profile.
Pooled data from the phase III READY clinical program demonstrated Relfydess’ rapid onset as early as day one and long duration of effect on frown lines and crow’s feet, with results sustained for over six months. Patient satisfaction remained high through to Month 6, and the treatment was well tolerated.
During the meeting, Galderma also hosted several educational sessions on its premium medical skincare brand Alastin, which offers full-spectrum care for patients undergoing aesthetic procedures to support the skin’s natural regenerative abilities and improve overall skincare results.
Contact:
Laurie Parks
Media.Relations@Galderma.com
+1 817 316 6199
Source: Galderma
